[6,6-2H2] D-glucose

Phase 1

CColumbia University

[6,6-2H2] D-glucose is one of 43 therapeutic programs targeting Insulin resistance. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Insulin ResistanceRecruiting

Insulin ResistancePhase 1

Recruiting

Competition

Competitive Landscape

65 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

15 2

Avandia

Jazz Pharmaceuticals

Approved

6 3

Glucophage

EMD Serono

Approved

17 4

Crestor

AstraZeneca

Approved

1 5

Rozerem

Takeda

Approved

1 6

Sovaldi

Gilead

Approved

1 7

Victoza

Novo Nordisk

Approved

1 8

Calciferol

Jazz Pharmaceuticals

Approved

—9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Starlix

Novartis

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Insulin Resistance

NCT06354088

Clinical

Trials by Indication[1]

Insulin resistance1 trial

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Recruiting·CColumbia University·Phase 1·NCT06354088·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [6,6-2H2] D-glucose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [6,6-2H2] D-glucose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Columbia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: CColumbia University

[6,6-2H2] D-glucose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News